Other News To Note
Monday, October 8, 2012
Deciphera Pharmaceuticals LLC, of Lawrence, Kan., said it plans to transition from an oncology discovery company to an oncology drug development company and will focus its resources on the continued development of rebastinib and DCC-2701, two drugs discovered using its switch pocket kinase inhibitor technology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.